Kuros Biosciences stock
KURN.SWSIXKuros Biosciences AG, HealthcareISIN CH0325814116
46Score 46 out of 100, Weak
Price and trend
53 / 100
Price history
−28% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 8.1% below it.
Since February 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 46).
The price is 38% below its 52-week high. Largest decline in 20 years: 100% (April 2007 to April 2023).
Chart figures for advanced users
- SMA 50$22.50
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$25.72
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)46
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$19.76
- The lowest closing price of the last twelve months.
- Resistance$38.41
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Kuros Biosciences AG belongs to the Medical (Devices) industry (Switzerland) and, with a market value of $940.07M, is number 61 of 88 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $200.27M (up 37.6%) and adjusted earnings per share of $0.32 (up 512.8%).
- MEQIRI Score 46 out of 100 (Weak): rank 436 of 702 in Healthcare, median 53.
Show more
- Our model puts fair value at $6.24, with the price 279% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 97.5% a year since 2020, Medical (Devices) median 13.8%.Growth 70
Weaknesses
- Above fair valuePrice 279% above the fair value of $6.24.Valuation 9
- DilutionShare count up 58% since 2020.Capital allocation 30
- Negative free cash flowFree cash flow −$7.94M over the last 12 months.Fundamentals 25
Its standout strengths are stability and growth, while fundamentals and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 47 to 46.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- price far below its 52-week high
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $4.46 and expensive above $10.41 (uncertainty high, based on the price swings of the past year).
Valuation metrics
From earnings times the industry P/E (29.1) alone; there are no viable cash flows for the cash-flow model.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 29.4% on the twelve months before. Revenue has grown strongly since 2006, at around 31% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 86%, operating 6%, net 2%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 3 Mar 2027in 110 days
- Last reported
- 13 Aug 2026EPS reported $0.11 (expected $0.07)above expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 4.3% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.32−4.3%
- Revenue
- $200.27M−2.6%
- Earnings per share
- $0.59−3.8%
- Revenue
- $256.03M−3.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −4.8%Guidance unchanged: about 35% growth in 2026, revenue of CHF 300 million to CHF 330 million and adjusted EBITDA margin above 20% by 2028; any update is considered in the third quarter.
“Our formal guidance remains revenue of $300 million to $330 million and an adjusted EBITDA margin of above 20% by 2028.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 13 Aug 2026 (fiscal Q2 2026), read by AI.
What happened at Kuros Biosciences
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 46
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- SI-BONESIBN $1.09B47
- AdaptHealthAHCO $1.07B32
- CeriBellCBLL $1.02B49
- ArtivionAORT $946.52M32
- OrthoPediatricsKIDS $850.68M47
- MedCapMCAP.ST $825.15M74
- Varex ImagingVREX $775.81M52
- InModeINMD $759.01M70
ETFs that hold Kuros Biosciences
Held by 7 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.06% | 0.40% | €813.42M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.04% | 0.30% | €3.45B |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.01% | 0.23% | €321.86M |
Show 3 more
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.84B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CHF 0.8331)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 12 Dec 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.